📢 Exclusive on Gate Square — #PROVE Creative Contest# is Now Live!
CandyDrop × Succinct (PROVE) — Trade to share 200,000 PROVE 👉 https://www.gate.com/announcements/article/46469
Futures Lucky Draw Challenge: Guaranteed 1 PROVE Airdrop per User 👉 https://www.gate.com/announcements/article/46491
🎁 Endless creativity · Rewards keep coming — Post to share 300 PROVE!
📅 Event PeriodAugust 12, 2025, 04:00 – August 17, 2025, 16:00 UTC
📌 How to Participate
1.Publish original content on Gate Square related to PROVE or the above activities (minimum 100 words; any format: analysis, tutorial, creativ
Fuhong Hanlin: The first patient has been dosed in the Hans joint chemotherapy first-line treatment ES-SCLC Japan bridge trial.
Jin10 data reported on June 24, the company Fuhong Hanlin announced that the first patient has been dosed in the Japanese bridge trial of Hanshuo (Surlulimumab Injection) combined with chemotherapy (Carboplatin-Etoposide) as the first-line treatment for extensive stage small cell lung cancer (ES-SCLC). This trial aims to support the market authorization application for Hanshuo in Japan. Previously, an international multi-center phase III clinical trial comparing Hanshuo or placebo combined with chemotherapy as the first-line treatment for ES-SCLC reached its primary endpoint of overall survival (OS) in December 2021.